Loading
A phase 3 trial of Pembrolizumab in melanoma, run by Iovance Biotherapeutics, Inc., now recruiting.
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. is a phase 3 interventional study registered as NCT05727904 by Iovance Biotherapeutics, Inc., with 670 participants planned, started 2023-03-30 and due to reach its primary completion in 2028-03-01. Interventions recorded: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period. Conditions listed: Metastatic Melanoma, Unresectable Melanoma, Melanoma. No results are recorded here; the registry entry is the source.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.